Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Amortization of Deferred Charges: 2017-2024

Historic Amortization of Deferred Charges for Tg Therapeutics (TGTX) over the last 8 years, with Dec 2024 value amounting to $2.0 million.

  • Tg Therapeutics' Amortization of Deferred Charges fell 26.57% to $304,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 47.88%. This contributed to the annual value of $2.0 million for FY2024, which is 16.11% down from last year.
  • Per Tg Therapeutics' latest filing, its Amortization of Deferred Charges stood at $2.0 million for FY2024, which was down 16.11% from $2.4 million recorded in FY2023.
  • Over the past 5 years, Tg Therapeutics' Amortization of Deferred Charges peaked at $2.4 million during FY2023, and registered a low of $925,000 during FY2020.
  • Its 3-year average for Amortization of Deferred Charges is $2.1 million, with a median of $2.0 million in 2024.
  • In the last 5 years, Tg Therapeutics' Amortization of Deferred Charges skyrocketed by 70.74% in 2022 and then decreased by 16.11% in 2024.
  • Yearly analysis of 5 years shows Tg Therapeutics' Amortization of Deferred Charges stood at $925,000 in 2020, then climbed by 16.76% to $1.1 million in 2021, then soared by 70.74% to $1.8 million in 2022, then increased by 28.96% to $2.4 million in 2023, then fell by 16.11% to $2.0 million in 2024.